BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 25301229)

  • 1. A review of neuraminidase inhibitor susceptibility in influenza strains.
    Spanakis N; Pitiriga V; Gennimata V; Tsakris A
    Expert Rev Anti Infect Ther; 2014 Nov; 12(11):1325-36. PubMed ID: 25301229
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuraminidase inhibitor resistance in influenza viruses and laboratory testing methods.
    Nguyen HT; Fry AM; Gubareva LV
    Antivir Ther; 2012; 17(1 Pt B):159-73. PubMed ID: 22311680
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuraminidase inhibitor susceptibility profile of pandemic and seasonal influenza viruses during the 2009-2010 and 2010-2011 influenza seasons in Japan.
    Dapat C; Kondo H; Dapat IC; Baranovich T; Suzuki Y; Shobugawa Y; Saito K; Saito R; Suzuki H
    Antiviral Res; 2013 Sep; 99(3):261-9. PubMed ID: 23791870
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comprehensive assessment of 2009 pandemic influenza A (H1N1) virus drug susceptibility in vitro.
    Gubareva LV; Trujillo AA; Okomo-Adhiambo M; Mishin VP; Deyde VM; Sleeman K; Nguyen HT; Sheu TG; Garten RJ; Shaw MW; Fry AM; Klimov AI
    Antivir Ther; 2010; 15(8):1151-9. PubMed ID: 21149922
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influenza virus resistance to antiviral therapy.
    van der Vries E; Schutten M; Fraaij P; Boucher C; Osterhaus A
    Adv Pharmacol; 2013; 67():217-46. PubMed ID: 23886002
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Screening for Neuraminidase Inhibitor Resistance Markers among Avian Influenza Viruses of the N4, N5, N6, and N8 Neuraminidase Subtypes.
    Choi WS; Jeong JH; Kwon JJ; Ahn SJ; Lloren KKS; Kwon HI; Chae HB; Hwang J; Kim MH; Kim CJ; Webby RJ; Govorkova EA; Choi YK; Baek YH; Song MS
    J Virol; 2018 Jan; 92(1):. PubMed ID: 29046464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the antiviral drug susceptibility of influenza viruses in Italy from 2004/05 to 2009/10 epidemics and from the recent 2009 pandemic.
    Puzelli S; Facchini M; Di Martino A; Fabiani C; Lackenby A; Zambon M; Donatelli I
    Antiviral Res; 2011 Jun; 90(3):205-12. PubMed ID: 21514326
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influenza virus resistance to neuraminidase inhibitors.
    Samson M; Pizzorno A; Abed Y; Boivin G
    Antiviral Res; 2013 May; 98(2):174-85. PubMed ID: 23523943
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuraminidase inhibitor resistance in influenza viruses.
    Reece PA
    J Med Virol; 2007 Oct; 79(10):1577-86. PubMed ID: 17705169
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Implications of Antiviral Resistance in Influenza.
    Li TC; Chan MC; Lee N
    Viruses; 2015 Sep; 7(9):4929-44. PubMed ID: 26389935
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent progress and challenges in the discovery of new neuraminidase inhibitors.
    Chamni S; De-Eknamkul W
    Expert Opin Ther Pat; 2013 Apr; 23(4):409-23. PubMed ID: 23369206
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Neuraminidase inhibitors resistance in influenza viruses and the related mechanisms].
    Huang L; Zhou JF; Wei H; Shu YL
    Bing Du Xue Bao; 2012 Sep; 28(5):572-6. PubMed ID: 23233936
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuraminidase inhibitor susceptibility testing of influenza type B viruses in China during 2010 and 2011 identifies viruses with reduced susceptibility to oseltamivir and zanamivir.
    Wang D; Sleeman K; Huang W; Nguyen HT; Levine M; Cheng Y; Li X; Tan M; Xing X; Xu X; Klimov AI; Gubareva LV; Shu Y
    Antiviral Res; 2013 Mar; 97(3):240-4. PubMed ID: 23267831
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influenza viruses resistant to neuraminidase inhibitors.
    Nitsch-Osuch A; Brydak LB
    Acta Biochim Pol; 2014; 61(3):505-8. PubMed ID: 25195142
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of influenza viruses resistant to neuraminidase inhibitors in global surveillance during the first 3 years of their use.
    Monto AS; McKimm-Breschkin JL; Macken C; Hampson AW; Hay A; Klimov A; Tashiro M; Webster RG; Aymard M; Hayden FG; Zambon M
    Antimicrob Agents Chemother; 2006 Jul; 50(7):2395-402. PubMed ID: 16801417
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systematic review of influenza resistance to the neuraminidase inhibitors.
    Thorlund K; Awad T; Boivin G; Thabane L
    BMC Infect Dis; 2011 May; 11():134. PubMed ID: 21592407
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Host cell selection of influenza neuraminidase variants: implications for drug resistance monitoring in A(H1N1) viruses.
    Okomo-Adhiambo M; Nguyen HT; Sleeman K; Sheu TG; Deyde VM; Garten RJ; Xu X; Shaw MW; Klimov AI; Gubareva LV
    Antiviral Res; 2010 Feb; 85(2):381-8. PubMed ID: 19917319
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro neuraminidase inhibitory activity of four neuraminidase inhibitors against influenza virus isolates in the 2011-2012 season in Japan.
    Ikematsu H; Kawai N; Iwaki N; Kashiwagi S
    J Infect Chemother; 2014 Feb; 20(2):77-80. PubMed ID: 24560563
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro activity of favipiravir and neuraminidase inhibitor combinations against oseltamivir-sensitive and oseltamivir-resistant pandemic influenza A (H1N1) virus.
    Tarbet EB; Vollmer AH; Hurst BL; Barnard DL; Furuta Y; Smee DF
    Arch Virol; 2014 Jun; 159(6):1279-91. PubMed ID: 24311151
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emergence and spread of oseltamivir-resistant A(H1N1) influenza viruses in Oceania, South East Asia and South Africa.
    Hurt AC; Ernest J; Deng YM; Iannello P; Besselaar TG; Birch C; Buchy P; Chittaganpitch M; Chiu SC; Dwyer D; Guigon A; Harrower B; Kei IP; Kok T; Lin C; McPhie K; Mohd A; Olveda R; Panayotou T; Rawlinson W; Scott L; Smith D; D'Souza H; Komadina N; Shaw R; Kelso A; Barr IG
    Antiviral Res; 2009 Jul; 83(1):90-3. PubMed ID: 19501261
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.